Navigation Links
Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™
Date:8/31/2011

Pty Ltd
Level 9, 278 Collins Street, Melbourne, 3000, Australia
www.hatchtech.com.au

About DeOvo™Despite its prevalence and high cost to the community, there have been few major advances in controlling head lice infestation in recent years. Most pediculicide products have little ovicidal activity and require two treatments (approximately 7 days apart), with the second application designed to treat those lice which have hatched from eggs that survive the first treatment. Non-compliance with this regimen and the difficulty in choosing the optimal time for the second application, are major difficulties in using these products. Hatchtech's DeOvo™, a topical formulation of a known metalloprotease inhibitor, has shown both ovicidal and lousicidal activity and offers the potential for a more effective treatment following a single application.

About PediculosisIt is estimated that 6-12 million people, in the United States, mainly children aged 3-12, are infested each year with head lice (Pediculus humanus capitis). The direct cost of treatment is estimated at several hundreds of millions of dollars. Added to this direct economic burden are the indirect costs including missed days from school, lost work productivity by parents who stay home to treat their children and costs borne by the school itself in trying to control or prevent this problem. The total costs have been estimated to be 1billion USD in the US alone.


'/>"/>

SOURCE Hatchtech Pty Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/22/2014)... Association for Molecular Pathology (AMP) released a report ... on recommendations for a molecular diagnostics curriculum ... education. The report was prepared by the Medical ... AMP Training and Education Committee. "Our goal was ... medical laboratory scientists appropriately in order to manage ...
(Date:4/22/2014)... the standard measurement for assessing glycemic control over time ... typically measured every few months in a laboratory, but ... estimates A1c using self-monitored blood glucose (SMBG) readings, as ... DTT ), a peer-reviewed journal from Mary Ann Liebert, ... DTT website at http://www.liebertpub.com/dtt . , ...
(Date:4/22/2014)... To help rein in massive health care spending, a ... urgently find ways to incentivize pharmaceutical companies and device ... Instead of examining existing medical technologies and their use, ... affect what drugs and medical devices get created in ... health care spending with as little loss of health ...
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
(Date:4/22/2014)... news release is available in German . ... Perutz Laboratories of the University of Vienna and the Medical ... have now shown how double stranded RNA, such as viral ... cell. During the immune response against viral infection, the protein ... There it modifies viral RNA to inhibit reproduction of the ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... The Reeve Foundation debuts new national ad campaign giving ... HILLS, N.J., Nov. 3 The Christopher & Dana ... advertising,campaign. The campaign presents an edgier side of the ... life is like through the eyes of,someone living with ...
... critical need to review current treatment strategies for the ... to a series of international papers in the November ... with severe disability, unmet treatment need and little clinical ... Professor David W Dodick from the Mayo Clinic College ...
... 3 Pregis Corporation, a leading,international manufacturer, ... specialty packaging solutions, will conduct an investor,conference ... results on Friday,November 14, 2008 at 10:00 ... 617-614-4909; Participant Passcode: 68623125. A replay of,the ...
... crucial element in hip,fracture recovery, ROSEMONT, Ill., ... fracture are referred to their primary care physicians ... published in the,November 2008 issue of The Journal ... an osteoporosis management program initiated by an,orthopaedic surgeon ...
... LifeNet Health,a leading allograft bio-implant company, ... United States Food and Drug Administration (FDA) ... technology., LifeNet Health received clearance for ... donor cells from cardiovascular tissues,while retaining the ...
... (Nasdaq: BMRN ) announced today the initiation ... with the lysosomal storage disease,Mucopolysaccharidosis Type IVA (MPS ... augment available data on the disease by measuring ... patients.,BioMarin expects to follow the MorCAP program with ...
Cached Medicine News:Health News:Christopher & Dana Reeve Foundation Launches First-Ever National Advertising Campaign 2Health News:Urgent need for research into the best treatment for medication overuse headaches 2Health News:Urgent need for research into the best treatment for medication overuse headaches 3Health News:Urgent need for research into the best treatment for medication overuse headaches 4Health News:Treating Osteoporosis After Hip Fracture 2Health News:Treating Osteoporosis After Hip Fracture 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: